The cat is out of the bag. A head to head tria of Avastin and Lucentis was completed. The results confirmed what most ophthalmologists believed that bevacizumab is not inferior to ranibizumab for the treatment of wet Age Related Macular Degeneration. Retina specialists for a long term have held this belief but until the results of the trial, the contention was unproven. The design of the trial did not establish equivalence but did reach the end point which proved non-inferiority.
We offer treatment of wet Age Related Macular Degeneration with the expertise of Dr. Mark Millsap, a fellowship trained and clinically experienced retina and vitreous specialist.